Netherlands· NL-38b90d33af0a

SCENESSE 16 mg, implantaat

A afamelanotide product containing afamelanotide, registered in Netherlands by Clinuvel Europe Limited. The same ATC class is registered in 10 of our 19 countries.

ATC D02BB02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about afamelanotideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Afamelanotide is registered in 10 of 19 countries.

Countries holding a registration under ATC D02BB02 (afamelanotide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
6 of them publish a price we can compare per daily dose

Search afamelanotide products by name

Afamelanotide · ATC D02BB02

10 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AFAMELANOTIDE
Manufacturer: Clinuvel Europe Limited
Country: Netherlands (NL)
ATC code: D02BB02
ATC class: Afamelanotide
Defined daily dose: 0.00822 DE, Implantat
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/14/969

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Afamelanotide in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afamelanotide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Scenesse
Liechtenstein · Scenesse
Norway · Scenesse

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/74e88d4e-814f-4259-95ca-3ca342586052
GET /v1/drugs/74e88d4e-814f-4259-95ca-3ca342586052?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Implantaat",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/scenesse-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Afamelanotide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp111817",
  "excipients": [
    "MELKZUUR (D,L)-GLYCOLZUUR COPOLYMEER LAURYLESTER",
    "MELKZUUR (D,L)-GLYCOLZUUR COPOLYMEER LAURYLESTER"
  ],
  "substances": [
    "AFAMELANOTIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/12/22",
  "procedure_number": "EMEA/H/C/002548",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/969",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about afamelanotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console